Expired CME Article

Algorithm for the Management of Osteoporosis

Authors: Ronald C. Hamdy, MD, FRCP, FACP, Sanford Baim, MD, FACR, Susan B. Broy, MD, FACP, FACR, CCD, E. Michael Lewiecki, MD, FACP, FACE, Sarah L. Morgan, MD, MS, RD, FADA, FACP, CCD, S. Bobo Tanner, MD, Howard F. Williamson, MD, FACOG

Abstract

Osteoporosis is a common skeletal disease that weakens bones and increases the risk of fractures. It affects about one half of women over the age of 60, and one third of older men. With appropriate care, osteoporosis can be prevented; and when present, it can be easily diagnosed and managed. Unfortunately, many patients with osteoporosis are not recognized or treated, even after sustaining a low-trauma fracture. Even when treatment is initiated, patients may not take medication correctly, regularly, or for a sufficient amount of time to receive the benefit of fracture risk reduction. Efforts to improve compliance and treatment outcomes include longer dosing intervals and parenteral administration. Clinical practice guidelines for the prevention and treatment of osteoporosis have been developed by the National Osteoporosis Foundation (NOF) but may not be fully utilized by clinicians who must deal with numerous healthcare priorities. We present an algorithm to help streamline the work of busy clinicians so they can efficiently provide state-of-the-art care to patients with osteoporosis.

This content is limited to qualifying members.

Existing members, please login first

If you have an existing account please login now to access this article or view purchase options.

Purchase only this article ($25)

Create a free account, then purchase this article to download or access it online for 24 hours.

Purchase an SMJ online subscription ($75)

Create a free account, then purchase a subscription to get complete access to all articles for a full year.

Purchase a membership plan (fees vary)

Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.

References

1. Consensus Development Conference 1991: prophylaxis and treatment of osteoporosis. Am J Med 1991;90:107–110.
 
2. NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy. Osteoporosis prevention, diagnosis, and therapy. JAMA 2001;285:785–795.
 
3. Burge RT, Dawson-Hughes B, Solomon D, et al. Incidence and economic burden of osteoporosis-related fractures in the United States, 2005–2025. J Bone Miner Res 2007;22:465–475.
 
4. Riggs BL, Melton LJ III. The worldwide problem of osteoporosis: insights afforded by epidemiology. Bone 1995;17(5 suppl):505S–511S.
 
5. American Heart Association and American Stroke Association. Heart Disease and Stroke Statistics: 2007 Update at-a-Glance. Dallas, American Heart Association, 2007. Available at:http://www.americanheart.org/downloadable/heart/1166712318459HS_StatsInsideText.pdf. Accessed April 27, 2010.
 
6. American Cancer Society. Cancer Facts and Figures 2009. Atlanta, American Cancer Society. 2009. Available at: http://www.cancer.org/downloads/STT/500809web.pdf. Accessed April 27, 2010.
 
7. Hooven F, Gehlbach SH, Pekow P, et al. Follow-up treatment for osteoporosis after fracture.Osteoporosis Int 2005;16:296–301.
 
8. Siris ES, Bilezikian JP, Rubin MR, et al. Pins and plaster aren't enough: a call for the evaluation and treatment of patients with osteoporotic fractures. J Clin Endocrinol Metab 2003;88:3482–3486.
 
9. Castel H, Bonneh DY, Sherf M, et al. Awareness of osteoporosis and compliance with management guidelines in patients with newly diagnosed low-impact fractures. Osteoporosis Int 2001;12:559–564.
 
10.Gold DT, Silverman SL. Compliance with osteoporosis medications: challenges for healthcare providers. Medscape Ob/Gyn Womens Health. 2005. Available at: www.medscape.com/viewarticle/503214. Accessed September 26, 2006.
 
11. Gass M, Dawson-Hughes B. Preventing osteoporosis-related fractures: an overview. Am J Med2006;119(4 suppl 1):S3–S11.
 
12. Edwards BJ, Bunta AD, Madison LD, et al. An osteoporosis and fracture intervention program increases the diagnosis and treatment for osteoporosis for patients with minimal trauma fractures. Jt Comm J Qual Patient Saf 2005;31:267–274.
 
13. Stafford RS, Drieling RL, Johns R, et al. National patterns of calcium use in osteoporosis in the United States. J Reprod Med 2005;50(suppl 11):885–890.
 
14. Ott S. Osteoporosis and Bone Physiology. Available at: http://courses.washington.edu/bonephys/. Updated July 2, 2007. Accessed February 18, 2010.
 
15. U.S. Department of Health and Human Services. Bone Health and Osteoporosis: A Report of the Surgeon General. Rockville, U.S. Department of Health and Human Services, Office of the Surgeon General, 2004.
 
16. Elliot-Gibson V, Bogoch ER, Jamal SA, et al. Practice patterns in the diagnosis and treatment of osteoporosis after a fragility fracture: a systematic review. Osteoporos Int 2004;15:767–778.
 
17. Jennings LA, Auerbach AD, Maselli J, et al. Missed opportunities for osteoporosis treatment in patients hospitalized for hip fracture. J Am Geriatr Soc 2010;58:650–657.
 
18.National Osteoporosis Foundation. Clinician's Guide to Prevention and Treatment of Osteoporosis. Washington, DC, National Osteoporosis Foundation, 2008. Available at: www.nof.org/physguide. Accessed February 18, 2010.
 
19. International Society for Clinical Densitometry. 2007 Official Positions and Official Pediatric Positions. Available at: http://www.iscd.org/Visitors/pdfs/ISCD2007OfficialPositions-Combined-AdultandPediatric.pdf. Accessed February 7, 2010.
 
20. North American Menopause Society. Management of osteoporosis in postmenopausal women: 2006 position statement of the North American Menopause Society. Menopause 2006;13:340–367.
 
21. U.S. Preventive Services Task Force. Screening for osteoporosis in postmenopausal women: recommendations and rationale. Ann Intern Med 2002;137:526–528.
 
22. Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update. American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced Osteoporosis. Arthritis Rheum 2001;44:1496–1503.
 
23. Centers for Medicare and Medicaid Services. Medicare preventive services: bone mass measurements. Available at: http://www.cms.gov/MLNProducts/downloads/bone_mass.pdf. Department of Health and Human Services. Updated July 2009. Accessed April 26, 2010.
 
24. Cazzaniga ME, Mustacchi G, Pronzato P, et al; NORA Study Group. Adjuvant systemic treatment of early breast cancer: the NORA study. Ann Oncol 2006;17:1386–1392.
 
25. Kanis JA, Johnell O, Oden A, et al. FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos Int 2008;19:385–397.
 
26 .Cummings SR, Black DM, Thompson DE. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA1998;280:2077–2082.
 
27. Harris ST, Watts NB, Genant HK, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA 1999;282:1344–1352.
 
28. McClung MR, Geusens P, Miller PD, et al; Hip Intervention Program Study Group. Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 2001;344:333–340.
 
29. Chesnut CH, Skag A, Christiansen C, et al; Oral Ibandronate Osteoporosis Vertebral Fracture Trial in North America and Europe (BONE). Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 2004;19:1241–1249.
 
30. Black DM, Delmas PD, Eastell R, et al; HORIZON Pivotal Fracture Trial. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007;356:1809–1822.
 
31. Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 1999;282:637–645.
 
32.Chesnut CH III, Silverman S, Adriano K, et al. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the Prevent Recurrence of Osteoporotic Fractures study. Am J Med 2000;109:330–331.
33.Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001;344:1434–1441.
34. Cummings SR, San Martin J, McClung MR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. New Engl J Med 2009;361:756–765.
35. Sinaki M. Critical appraisal of physical rehabilitation measures after osteoporotic vertebral fracture. Osteoporos Int 2003;14:773–779; Erratum in: Osteoporos Int 2006;17:1702.
36. Heaney RP. The vitamin D requirement in health and disease. J Steroid Biochem Mol Biol 2005;97:13–19.
37. Garnero P, Delmas PD. Biochemical markers of bone turnover in osteoporosis, in Marcus M, Feldman D, Kelsey J (eds): Osteoporosis San Diego, Academic Press, 2001, vol 2, ed 2, pp 459–477.
38. Siris ES, Harris ST, Rosen CJ, et al. Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc 2006;81:1013–1022.
39. Ettinger MP, Gallagher R, Amonkar M. Medication persistence is improved with less frequent dosing of bisphosphonates but remains inadequate. Arthritis Rheum 2004;50(suppl):S513–S514. [Abstract 1325].